Sally Church's Page

New trends in Pharma: the growth of generics

Earlier this year, we were deep into a consulting report on general trends in the Pharma industry and were struck by data in different yearly reports from PhRMA, the industry body in the US. Basically, when we pieced the data...

The roller coaster of life

One of the things about running a consulting company is that life is more like a roller coaster than comfy slippers by the fire. The workload is extremely uneven and veers between insanely busy and very quiet, with little in...

What's hot in oncology? A review of 2009 and predictions for 2010

Back in February, I took a big picture look at some of the cancer drugs in development that might be reviewed by the FDA for approval in 2009. You can see the review here. Of the eight drugs that were...

There's no such thing as a free coffee in Pharma

Is a free cup of coffee in a conference exhibitor’s booth an inducement to prescribe? Image by Omar_MK via FlickrIt was interesting to see exhibitors at the recent American Society of Hematology meeting place conspicuous signs in booths that had...

Tarceva maintenance therapy in non-small cell lung cancer

Chomping at the bit, like many others today, to hear how the FDA ODAC meeting goes on regarding Tarceva maintenance therapy in lung cancer. The initial OSI company presentation appeared to go well, but Q&A session did not; the committee...